CellCura is delighted to announce that the Protein Free Media has been certified “halal” by the Halal Food Council of Europe (HFCE).
“This is an historic event. For the first time in the field of assisted reproductive technologies (ART), the Muslim community has a choice to use Halal products for their infertility treatment with the Halal certification of the PF Protein Free Media. Without any proteins of biological or engineered origin, these completely synthetic and ultra-pure culture media products allow people to undergo infertility treatment in complete accordance with their respective faiths” says Dr. Ali, inventor of protein-free technology and corporate advisor to CellCura.
CellCura is the first player globally to launch a unique and complete range of protein-free media products. The uniqueness is the absences of biological origin components in the formulation securing a superior quality control, improved product stability, unrivalled product consistency and elimination of risks of transmission of blood borne diseases. The Protein Free media products are currently being distributed and marketed through trials in selected markets in Asia, Middle East and Europe with very good results and with significant decrease in batch variances compared to competitive products.
About Halal Certification
Halal Certification requires a verified independent third party organization to audit the content and manufacture of products to be certified, attesting that these products conforms to the rigorous preparation and ingredient requirement standards for Halal.
About the Halal Food Council of Europe
The Halal Food Council of Europe (HFCE) was registered in Brussels, Belgium, in the year 2010, as an Islamic organization that is dedicated to research in the fields related to food and nutrition. HFCE is recognized & accredited by many Muslim government organizations around the world, such as Majelis Ulema Indonesia (MUI), Jabatan Kemajuan Islam Malaysia (JAKIM) & Majlis Ugama Islam Singapore (MUIS).
About CellCura ASA
Chief Executive Officer
CellCura ASA is dedicated to the development and sales of cell technologies for use in assisted reproductive technology (ART) and stem cell research worldwide, representing improved safety and efficiency compared to traditional technology. CellCura is listed on the Oslo Axess market at the Oslo Stock Exchange (ticker: CELL).
This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)